Effect of Daily Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Proteinuria in Pediatric Patients With Idiopathic Nephrotic Syndrome

NACompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 1, 2019

Primary Completion Date

March 1, 2021

Study Completion Date

December 1, 2021

Conditions
Idiopathic Nephrotic SyndromeFrequently Relapsing Nephrotic Syndrome
Interventions
DEVICE

Transcutaneous Auricular Vagus Nerve (taVNS) stimulation

Participants in this study will perform home transcutaneous auricular vagus nerve stimulation (taVNS) for 5 minutes a day for a 6-month period. The device that will be used is the commercially available Roscoe Medical TENS 7000 vagus nerve stimulator. The device will be attached to the Cymba Concha of the ear via an electrode ear clip. The intensity of the stimulation will be slowly increased and adjusted to individual tolerability for each treatment. TaVNS will be performed for 5 minutes daily for a period of 6 months.

Trial Locations (1)

11040

Northwell, New Hyde Park

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Northwell Health

OTHER

NCT04169776 - Effect of Daily Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Proteinuria in Pediatric Patients With Idiopathic Nephrotic Syndrome | Biotech Hunter | Biotech Hunter